Preferred Label : Voretigene Neparvovec;

UNII : 2SPI046IKD;

CAS number : 1646819-03-5;

NCI Metathesaurus CUI : CL787800;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3538246/fr/luxturna-voretigene-neparvovec-dystrophie-retinienne-hereditaire
2024
false
false
false
France
voretigene neparvovec
treatment outcome
insurance, health, reimbursement
adult
child
adolescent
vision disorders
evaluation of the transparency committee
retinal dystrophies
Hereditary Retinal Dystrophy
Voretigene Neparvovec

---
https://www.has-sante.fr/jcms/p_3456518/fr/luxturna-voretigene-neparvovec-dystrophie-retinienne-hereditaire
2023
false
false
false
France
Voretigene Neparvovec
treatment outcome
insurance, health, reimbursement
gene therapy
biological products
adult
child
retinal dystrophies
Biallelic RPE65, retinoid isomerohydrolase mutation associated retinal dystrophy (disorder)
RPE65 gene mutation
adolescent
Subretinal Route of Administration
voretigene neparvovec
evaluation of the transparency committee
hereditary retinal dystrophy, nos
retinal dystrophies

---
https://www.has-sante.fr/jcms/c_2964759/fr/luxturna
https://www.has-sante.fr/jcms/c_2964759/fr/luxturna-voretigene-neparvovec-therapie-genique
2019
false
true
false
false
France
French
treatment outcome
adult
child
orphan drug production
retinoid isomerohydrolase
retinoid isomerohydrolase
retinal dystrophies
retinal dystrophies
genetic therapy
injections
evaluation of the transparency committee
Voretigene Neparvovec
guidelines for drug use
cis-trans-isomerases
voretigene neparvovec
Hereditary Retinal Dystrophy
cis-trans-isomerases
cis-trans-isomerases

---
https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
adult
child
orphan drug production
retinoid isomerohydrolase
retinoid isomerohydrolase
retinal dystrophies
retinal dystrophies
genetic therapy
injections
product surveillance, postmarketing
pregnancy
breast feeding
drug evaluation, preclinical
voretigene neparvovec
Hereditary Retinal Dystrophy
Voretigene Neparvovec
Voretigene Neparvovec
cis-trans-isomerases
cis-trans-isomerases

---
https://www.has-sante.fr/jcms/c_2964759/fr/luxturna
2019
false
false
false
France
guidelines for drug use
Voretigene Neparvovec
Hereditary Retinal Dystrophy
adult
child
injections
treatment outcome
evaluation of the transparency committee
genetic therapy
gene therapy

---
Nous contacter.
01/11/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.